Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET

Company Participants

Alex Braun - Head-Investor Relations

Dan O'Connell - Chief Executive Officer

Eric Siemers - Chief Medical Officer

Matt Zuga - Chief Financial Officer & Chief Business Officer

Conference Call Participants

Colin Bristow - UBS

Paul Matteis - Stifel

Tom Shrader - BTIG

Pete Stavropoulos - Cantor Fitzgerald

Charlie Yang - Bank of America

Operator

Thank you for standing by, and welcome to the Acumen Pharmaceuticals Second Quarter 2023 Update Call. At this time, all participants are in a listen-only mode. There will be a brief overview followed by question-and-answer session. [Operator Instructions] Today's call is being recorded.

And I would now like to turn the call over to Alex Braun, Head of Investor Relations. Please go ahead.

Alex Braun

Thank you, Lisa. Good morning and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended June 30, 2023. With me today are Dan O'Connell, our Chief Executive Officer; Dr. Eric Siemers, our Chief Medical Officer; and Matt Zuga, our Chief Financial Officer and Chief Business Officer.

Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issued this morning and related slide presentation we'll discuss today. Please note that during today's conference call, we may make forward-looking statements within the meaning of the Federal Securities Laws, including statements concerning our financial outlook and expected business plans. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Please see slide 2 of the accompanying presentation, our press release issued this morning and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments. After our prepared remarks we'll open the call for Q&A.

Now I'll turn the call over to Dan.

Dan O'Connell

Thanks, Alex. Good morning, and thanks to everyone who has joined us today. A few weeks ago Acumen presented compelling clinical data in support of ACU193, our asset for the treatment of early Alzheimer's disease. Our positive Phase I top-line results solidify ACU193's potential as a future option in the Alzheimer's treatment paradigm. The success of our novel target engagement assay, robust study design and committed execution enabled us to demonstrate convincing proof of mechanism inclusive of significant amyloid plaque reduction.